Showing 98,801 - 98,820 results of 102,147 for search '(( 2 step decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.70s Refine Results
  1. 98801

    Image_3_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  2. 98802

    Cell Types and their Rules. by Bryan Shin (17833689)

    Published 2024
    “…Simulation experiments then revealed significantly decreased B-cell responsiveness as levels of background chronic inflammation increased, reproducing the different COVID-19 infection data seen in a VA population.…”
  3. 98803

    Data_Sheet_2_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  4. 98804

    Table_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  5. 98805
  6. 98806

    Image_2_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  7. 98807

    Cytokines, Chemokines, and their Functions. by Bryan Shin (17833689)

    Published 2024
    “…Simulation experiments then revealed significantly decreased B-cell responsiveness as levels of background chronic inflammation increased, reproducing the different COVID-19 infection data seen in a VA population.…”
  8. 98808

    Image_4_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  9. 98809

    Data_Sheet_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  10. 98810

    Image_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  11. 98811

    Image_6_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  12. 98812
  13. 98813
  14. 98814
  15. 98815
  16. 98816

    Data Sheet 1_Exploring the therapeutic potential of “Zhi-Zhen” formula for oxaliplatin resistance in colorectal cancer: an integrated study combining UPLC-QTOF-MS/MS, bioinformatic... by Yongjing Li (3821944)

    Published 2025
    “…Background<p>Chemoresistance is a critical factor compromising the survival of patients with colorectal cancer (CRC). …”
  17. 98817
  18. 98818
  19. 98819
  20. 98820